Department of Medicine, Northwell Health, Lenox Hill Hospital, New York, NY, 10075, USA.
Division of Gastroenterology, Northwell Health, Lenox Hill Hospital, New York, NY, 10075, USA.
Adv Ther. 2021 Jul;38(7):4152-4161. doi: 10.1007/s12325-021-01805-8. Epub 2021 Jun 10.
Although still not approved at the federal level for medical or adult recreational use, cannabis has been approved in the United States (USA) by individual states for both of these purposes. A total of 15 states now regulate cannabis for adult use and 36 states for medical use. In more recent years, cannabis has gained popularity for the treatment of chronic conditions, inflammatory bowel disease (IBD) being one of them. However, the exact role of cannabis in the treatment of IBD remains uncertain. While cannabis may help in some instances with symptom management, it has not been proven to help with inflammation or to fundamentally correct underlying disease processes. Additionally, along with the perceived symptom benefits of cannabis come concerning issues like dosing inconsistencies, dependence, and cannabinoid hyperemesis syndrome. In this review article, we explore the nuanced relationship between cannabis and the treatment of IBD by summarizing the current research. We also use clinical vignettes to discuss the more practical considerations surrounding its use.
虽然大麻在联邦层面上仍未被批准用于医疗或成人娱乐用途，但在美国（USA）的个别州已经批准了这两种用途。现在共有 15 个州将大麻用于成人娱乐，36 个州用于医疗用途。近年来，大麻因其治疗慢性疾病而广受欢迎，炎症性肠病（IBD）就是其中之一。然而，大麻在治疗 IBD 中的确切作用仍然不确定。虽然大麻在某些情况下可能有助于控制症状，但它尚未被证明有助于缓解炎症或从根本上纠正潜在的疾病过程。此外，除了大麻被认为可以缓解症状之外，还存在一些令人担忧的问题，如剂量不一致、依赖性和大麻素呕吐综合征。在这篇综述文章中，我们通过总结当前的研究来探讨大麻与 IBD 治疗之间的微妙关系。我们还使用临床病例讨论来讨论围绕其使用的更实际的考虑因素。
